Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center

Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center

Background/Aim. To evaluate the clinical efficacy of FOLFOX4 (5-fluomumcil/leucovorin combined and oxaliplatin) neoadjuvant chemotherapy for advanced gastric cancer (AGC). Patients and Methods. Fifty-eight AGC patients were enrolled in this retrospective cohort study, 23 in the neoadjuvant group and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhen Sun, Rui-Juan Zhu, Gui-Fang Yang, Yan Li
Format:	Article
Language:	English
Published:	Wiley 2014-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1155/2014/418694
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of Neoadjuvant Chemotherapy With FLOT and Modified DCF Regimens in Nonmetastatic Gastric Adenocarcinoma
by: Mehdi Pourghasemian, et al.
Published: (2025-06-01)

Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma
by: Lin Liu, et al.
Published: (2025-07-01)

A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers
by: Qiuyao Zeng, et al.
Published: (2025-01-01)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
by: Bożena Cybulska-Stopa, et al.
Published: (2020-03-01)

Does neoadjuvant chemotherapy increase the survival in patients with locally advanced gastric cancer patients? – A real-world evidence
by: Murugesan Janarthinakani, et al.
Published: (2020-01-01)

Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer
by: Vo Duy Long, et al.
Published: (2024-12-01)

Clinical case of pathological complete response of gastric cancer after one cycle of neoadjuvant chemotherapy with fot regimen
by: V. Yu. Skoropad, et al.
Published: (2023-01-01)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
by: Narimane Salmi, et al.
Published: (2014-01-01)

The impact of delayed adjuvant chemotherapy on survival in gastric cancer patients with and without preoperative chemotherapy
by: Masataka Shimonosono, et al.
Published: (2025-07-01)

Do Nutritional and Inflammatory Indices Predict Response in Geriatric Gastric Cancer Patients Treated with Neoadjuvant FLOT Regimen?
by: Yonca Yılmaz Ürün MD, et al.
Published: (2025-04-01)

Long‐term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma
by: Lin Lu, et al.
Published: (2025-06-01)

Response: Do Nutritional and Inflammatory Indices Predict Response in Geriatric Gastric Cancer Patients Treated With Neoadjuvant FLOT Regimen?
by: Yonca Yılmaz Ürün MD, et al.
Published: (2025-06-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Effect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II–IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial
by: Raziyeh Kheshti, et al.
Published: (2025-05-01)

Letter to the Editor: Do Nutritional and Inflammatory Indices Predict Response in Geriatric Gastric Cancer Patients Treated With Neoadjuvant FLOT Regimen?
by: Aybala Nur Ucgul MD
Published: (2025-06-01)

Radiomic-based models are able to predict the pathologic response to different neoadjuvant chemotherapy regimens in patients with gastric and gastroesophageal cancer: a cohort study
by: Annamaria Agnes, et al.
Published: (2025-05-01)

Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy
by: Jiao-Bao Huang, et al.
Published: (2025-01-01)

Impact of pathological complete response on survival in gastric cancer after neoadjuvant chemotherapy: a propensity score matching analysis
by: Yonghe Chen, et al.
Published: (2025-01-01)

Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
by: Qi He, et al.
Published: (2017-04-01)

Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
by: Chia-Ling Chiang, et al.
Published: (2025-06-01)

Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer
by: Shanshan Bu, et al.
Published: (2025-04-01)

Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study
by: Hua-Long Zheng, et al.
Published: (2025-12-01)

FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER
by: Emine Yıldırım, et al.
Published: (2022-01-01)

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
by: Jessica Young, et al.
Published: (2024-11-01)

Use of Cox’s Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response
by: Junichi Asano, et al.
Published: (2013-01-01)

Bilateral optic neuropathy in Krukenberg tumor treated with FOLFOX plus nivolumab: a case report
by: Junwoo Lee, et al.
Published: (2025-04-01)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
by: Upasana Baruah, et al.
Published: (2015-01-01)

MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens
by: Chengyue Wu, et al.
Published: (2025-04-01)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
by: Young Shin Chung, et al.
Published: (2017-01-01)

mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemother apy in locally advanced rectal cancer:a propensity score matching analysis
by: Qiu Meng
Published: (2022-04-01)

Pathological Complete Response and Long-Term Survival in a Very Elderly Patient after Neoadjuvant Chemotherapy for Locally Advanced, Unresectable Gastric Cancer
by: Kunihiko Izuishi, et al.
Published: (2014-01-01)

Analysis of the safety and efficacy of laparoscopic gastrojejunostomy following neoadjuvant chemotherapy for gastric pyloric obstruction
by: Bo Hu, et al.
Published: (2025-03-01)

Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
by: A. V. Avgustinovich, et al.
Published: (2022-03-01)

Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results
by: M. V. Sedova, et al.
Published: (2023-09-01)

Personalizing neoadjuvant chemotherapy regimens for triple-negative breast cancer using a biology-based digital twin
by: Chase Christenson, et al.
Published: (2025-05-01)

KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01)

A multicenter retrospective study of the combination of immune checkpoint inhibitors and chemotherapy regimens with or without liver metastasis for the first-line treatment of advanced gastric cancer
by: Jing Ren, et al.
Published: (2024-12-01)

The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer
by: Farhad Ghasemi, et al.
Published: (2024-10-01)

Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events
by: Min Li, et al.
Published: (2024-12-01)

Unraveling the role of gut microbiome in predicting adverse events in neoadjuvant therapy for rectal cancer
by: Jingxin Ma, et al.
Published: (2024-12-01)